Novo Nordisk (NVO.N): Semaglutide can reduce the risk of myocardial infarction and stroke by 25%, and is associated with a 25% reduction in the overall risk of major adverse cardiovascular events such as myocardial infarction, stroke, hospitalization for unstable angina or heart failure, and death.